A practical reference on Thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
The PRIs are higher than the U.S. RDAs, with the exception of pregnancy. The EFSA reviewed the same safety question did not establish a UL. Infants may require iron supplements if they are bottle-fed cow's milk. Frequent blood donors are at risk of low iron levels and are often advised to supplement their iron intake. For U.S. food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value (%DV). For iron labeling purposes, 100% of the Daily Value was 18 mg, and as of May 27, 2016 remained unchanged at 18 mg. A table of the old and new adult daily values is provided at Reference Daily Intake.
=== Acute kidney injury (previously termed acute renal failure) === The ratio is predictive of prerenal injury when BUN:Cr exceeds 20 or when urea:Cr exceeds 100. In prerenal injury, urea increases disproportionately to creatinine due to enhanced proximal tubular reabsorption that follows the enhanced transport of sodium and water.
== Biography == In 1964 Bernd Michael Rode graduated from high school (“Akademisches Gymnasium Innsbruck”) and commenced studies in chemistry at the University of Innsbruck. In 1973 he received his Ph.D. degree in chemistry with sub auspiciis praesidentis from the University of Innsbruck. In 1973 Prof. Rode started his career as an assistant professor at the Institute of Inorganic and Analytical Chemistry of the University of Innsbruck. After research stays in Germany (University of Stuttgart and University of Karlsruhe) he became an associate professor in Innsbruck in the year 1976. After spending a 1-year research stay at the University of Tokyo, Prof. Rode started his professorship at the Institute of Inorganic and Theoretical Chemistry at the University of Innsbruck. From 2006 to 2011 he was head of the Department of Theoretical Chemistry and head of the Institute for General Inorganic and Theoretical Chemistry. One of Prof. Rode’s largest achievements was the foundation of the University Network ASEA-UNINET (Austrian South East Asian University Partnership Network) in 1994. The foundations for this network were laid by informal contacts between the University of Innsbruck and Thai Universities that date back to the 1970s. In the 1980s partnerships between the University of Innsbruck, the University of Vienna, the University of Agricultural Sciences Vienna, the Chulalongkorn University, the Mahidol University, the Kasetsart University and the Chiang Mai University were concluded.
=== Pre-industrial technology === Nanoparticles were used by artisans since prehistory, albeit without knowledge of their nature. They were used by glassmakers and potters in Classical Antiquity, as exemplified by the Roman Lycurgus cup of dichroic glass (4th century CE) and the lusterware pottery of Mesopotamia (9th century CE). The latter is characterized by silver and copper nanoparticles dispersed in the glassy glaze.
Sources: en.wikipedia.org
== Signs and symptoms == Children with sJIA are frequently severely unwell when diagnosed. They often have lost weight and are tired, feverish, experiencing myalgia and arthralgia, as well as occasional chest and stomach pain. These characteristics may overshadow the arthritis in the early stages of the disease. The presence of fever at presentation is practically universal in those with sJIA. The distinctive fever pattern associated with sJIA is characterized by temperatures that surge above 39 °C once or twice a day and then quickly fall to normal or below baseline. More than 80% of patients have a salmon-colored macular or maculopapular rash that appears along with their fever. Urticarial rash is less prevalent. The eruption is usually limited to the trunk, neck, and proximal extremities, but it might spread more widely. Macules typically measure less than 5 mm in diameter, while bigger macules may be present with center fading. The degree of erythema varies in the same patient, however, it is usually migratory and nonpruritic. The existence of arthritis must be validated before meeting the diagnostic criteria. Although arthralgias are often present at onset, arthritis may not be visible at first and can develop weeks, months, or even years later. Additionally, there is a wide range of joint involvement, from polyarticular patterns to oligoarticular patterns (four or fewer joints with arthritis). The wrists, knees, and ankles are the joints that are most frequently affected.
=== Awards === Counter-Strike earned numerous accolades on its release. In 2000, it was recognized by many gaming magazines and websites as Game of the Year, Action Game of the Year, or Online Game of the Year. The game also won 2 reader polls for Game of the Year from GameSpot US and VoodooExtreme readers. At the Game Developer 2001 Spotlight Awards, Counter-Strike was named Best Multiplayer Game and received a Special Achievement in Gaming. In 2003, Counter-Strike was inducted into GameSpot's greatest games of all-time list.
== Mechanism == It is a member of the secretin family of G protein-coupled receptors. The activity of this receptor is mediated by Gs protein, which activates adenylyl cyclase. Besides this, they also activate the phosphatidylinositol-calcium second messenger system.
The narrower Russell Top 50 Mega Cap Index consists of the 50 largest companies in the Russell 3000 at the time of index reconstitution. As of April 30, 2026, the Russell Top 50 Mega Cap Index contained 51 constituents, with market caps ranging from $216.6 billion to $4.85 trillion. The even narrower Russell Top 10 Index consists of the 10 largest companies in the Russell 3000 at the time of index reconstitution. As of May 29, 2026, the Russell Top 10 Index contained 11 constituents, with market caps ranging from $873 billion to $4.93 trillion. A 2025 article by S&P Dow Jones Indices describes its own S&P 100, S&P 500 Top 50 (ticker: SP5T5), S&P 500 Top 20 (ticker: SP5T2), and S&P 500 Top 10 (ticker: SP5T1) indices as "mega-cap indices". As of May 29, 2026, the S&P 100 index's methodology required a minimum market cap of $22.7 billion, and the index's 101 constituents had actual market caps ranging from $55.1 billion to $5.13 trillion. As of May 29, 2026, the S&P 500 Top 50 Index contained 51 constituents, with market caps ranging from $92.3 billion to $5.13 trillion. Invesco issues an index ETF (NYSE Arca: XLG) that tracks the S&P 500 Top 50 Index. As of May 29, 2026, the S&P 500 Top 20 Index contained 21 constituents, with market caps ranging from $316 billion to $5.13 trillion. The S&P 500 Top 20 Select Index (ticker: SPXT2SUP) is a capped variant of the S&P 500 Top 20 Index, limiting any single company's weight in the index to a maximum of 22.5%, and limiting companies with weights above 4.5% to collectively constitute at most 48% of the index's weight.
Five children with cerebral folate deficiency and low functioning autism with neurological deficits found a complete reduction of ASD symptoms with the use of folinic acid in a child and substantial improvements in communication in two other children.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.